[1]
Xu, W. 2026. CRISPR/Cas9-Mediated PD-1 Engineered T Cells: New Strategy to Block Tumor Immune Escape. International Journal of Biology and Life Sciences. 16, 1 (Aug. 2026), 252–255. DOI:https://doi.org/10.54097/edfqwy74.